Non-Steroidal Anti-inflammatory Drugs Market Set To Grow From $23.31 Billion In 2026 To $29.95 Billion By 2030 At A CAGR Of 6.5%
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Non-Steroidal Anti-inflammatory Drugs Market Forecast Highlighting Growth From $23.31 Billion To $29.95 Billion
The market valuation for non-steroidal anti-inflammatory drugs has experienced robust expansion in recent years, projected to increase from $21.89 billion in 2025 to $23.31 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.5%. This historical growth has been driven by a higher incidence of arthritis and musculoskeletal conditions, enhanced understanding of pain management treatments, growth within the elderly demographic, a broader network of retail pharmacies, and improvements in drug formulation technologies.
Analysts anticipate considerable expansion for the market of non-steroidal anti-inflammatory drugs over the coming years. By 2030, the market is projected to reach $29.96 billion, reflecting a compound annual growth rate (CAGR) of 6.5%. This upward trajectory in the forecast period is largely influenced by factors such as the embrace of personalized medicine, the growing prominence of e-pharmacy platforms, heightened research and development efforts into innovative NSAID formulations, a higher prevalence of chronic inflammatory conditions, and the incorporation of digital health technologies for pain tracking. Key developments shaping this period include tailored approaches to pain management, an increased preference for over-the-counter anti-inflammatory medications, the introduction of fast-acting drug versions, a concentrated effort on managing chronic pain and arthritis, and the broadening reach of online pharmacies.
Download A Free Sample Report For Comprehensive Market Insights:
Non-Steroidal Anti-inflammatory Drugs Market Industry Drivers: What Is Driving Revenue Growth?
The anticipated expansion of the non-steroidal anti-inflammatory drug market is being driven by the growing frequency of musculoskeletal disorders. Musculoskeletal disorders (MSDs) encompass a wide range of conditions affecting the musculoskeletal system, including muscles, bones, tendons, ligaments, joints, and connective tissues. Non-steroidal anti-inflammatory drugs (NSAIDs) are essential for alleviating pain and inflammation linked to disorders like arthritis, osteoarthritis, and rheumatoid arthritis. Key factors fueling this expansion include an aging population, heightened awareness and diagnosis of musculoskeletal issues, orthopedic surgeries, sports injuries, and the persistent nature of these ailments. For example, in January 2024, data from GOV.UK, a UK government agency, indicated that 18.4% of individuals aged 16 and older reported having a long-term musculoskeletal (MSK) condition in 2023, up from 17.6% in 2022. Consequently, the rising incidence of musculoskeletal disorders is fueling growth in the non-steroidal anti-inflammatory drugs market.
The growth of the non-steroidal anti-inflammatory drugs (NSAIDs) market and related pain management solutions is being propelled by the escalating rate of chronic pain. Chronic pain is defined as ongoing or recurring pain lasting three months or longer, originating from conditions like arthritis, fibromyalgia, back pain, neuropathic pain, and other musculoskeletal disorders. Such conditions profoundly impact patients’ quality of life, often necessitating long-term management through medication, physical therapy, and supportive care. The increasing occurrence of chronic pain raises the demand for effective pain relief options, including NSAIDs and other analgesic products. As reported in October 2024 by the National Center for Biotechnology Information, a US-based federal research entity, 24.3% of adults experienced chronic pain, with 8.5% facing high-impact chronic pain that restricts daily activities. Hence, the expanding population of individuals enduring chronic pain is expected to boost the need for pain management therapies, thereby fostering the expansion of the NSAIDs market and associated products.
Non-Steroidal Anti-inflammatory Drugs Market Segment Analysis: What Are The Major Market Categories?
The non-steroidal anti-inflammatory drugs market covered in this report is segmented –
1) By Route Of Administration: Oral, Topical, Other Route Of Administration
2) By Disease Indication: Arthritis, Migraine, Ophthalmic Diseases, Other Disease Indications
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Oral: Tablets, Capsules, Liquids Or Solutions
2) By Topical: Gels, Creams, Patches
3) By Other Route Of Administration: Injectable (Intravenous And Intramuscular), Suppositories
Non-Steroidal Anti-inflammatory Drugs Market Growth Trends: What Is Influencing The Future Outlook?
Major players in the non-steroidal anti-inflammatory drugs (NSAIDs) market are increasingly prioritizing the creation of advanced products like combination analgesic–gastroprotective formulations to address the growing need for effective pain management that comes with lower gastrointestinal risks, a common concern linked to extended NSAID usage. By integrating an NSAID with a protective compound, these innovative systems preserve anti-inflammatory benefits while reducing stomach discomfort, presenting a safer option compared to conventional single-component NSAIDs. A notable example is Endo International plc, a pharmaceutical company based in Ireland, which introduced ibuprofen-famotidine 800 mg/26.6 mg tablets in March 2024. This sophisticated formulation merges the pain-relieving and anti-inflammatory properties of ibuprofen with the stomach-protective abilities of famotidine, aiming to deliver relief while lowering side effects like ulcers or irritation that frequently accompany prolonged NSAID treatment, thereby boosting safety and encouraging better patient compliance.
Non-Steroidal Anti-inflammatory Drugs Market Leading Companies Driving Competitive Growth
Major companies operating in the non-steroidal anti-inflammatory drugs market are Pfizer Inc., Bayer AG, Johnson & Johnson, Sun Pharmaceutical Industries Ltd., Assertio Therapeutics Inc., Iroko Pharmaceuticals Inc., Perrigo Company PLC, Hikma Pharmaceuticals PLC, Glenmark Pharmaceuticals Limited, Aspen Pharmacare Holdings Limited, Sagent Pharmaceuticals Inc., Advanced Pharma Inc., Akorn Operating Company LLC, Alembic Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Lupin Limited, Cipla Limited, Zydus Cadila Healthcare Limited, Aurobindo Pharma Limited, Sanofi S.A., GlaxoSmithKline PLC, Horizon Therapeutics PLC, Novartis AG, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company
Access The Complete Non-Steroidal Anti-inflammatory Drugs Market Report:
Non-Steroidal Anti-inflammatory Drugs Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the non-steroidal anti-inflammatory drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the non-steroidal anti-inflammatory drugs market during the forecast period. The regions covered in the non-steroidal anti-inflammatory drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
